PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

Free Press Journal, Mumbai
Thursday 30th January 2014, Page: 19
Width: 4.30 cms, Height: 14.81 cms, a4, Ref: pmin.2014-01-31.10.15

Now, Ranbaxy comes under EU, UK scanner

Hyderabad

Days after the US Food and Drug Administration banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU and the UK have said they are evaluating the FDA inspection findings to assess if deviations from GMP have any implication in their markets.

European Medicines Agency (EMA), a body under the European Union, said Ranbaxy Laboratories site in Toansa, Punjab is a supplier of active ingredients for four centrally authorised medicines Enyglid (repaglinide), Repaglinide Krka (repaglinide), Repaglinide Teva (repaglinide) and Nevirapine Teva (nevirapine), besides several non-centrally authorised medicines.

Citing manufacturing norm violations, FDA prohibited Ranbaxy Laboratories from distributing drugs produced at the Toansa unit in the US, including medicines made by the company's Ohm Laboratories facility in New Jersey.

Regulatory / company